Alkermes plc.
Alkermes plc (Nasdaq: ALKS) is a biopharmaceutical company focused on developing medicines in neuroscience. Its U.S. commercial portfolio includes ARISTADA and ARISTADA INITIO for schizophrenia, LYBALVI for schizophrenia and bipolar I disorder, VIVITROL for alcohol and opioid dependence, and LUMRYZ for narcolepsy. The… From the company’s description.
In fiscal 2025, Alkermes plc. reported revenue of $1.48B, down 5.2% from fiscal 2024, and net income of $241.66M. Its operating margin was 17.2%, and operations generated $520.75M in cash. Over the twelve months to Jun 30, 2026, revenue was $1.67B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Alkermes plc. does
In the company’s own words
Alkermes plc (Nasdaq: ALKS) is a biopharmaceutical company focused on developing medicines in neuroscience. Its U.S. commercial portfolio includes ARISTADA and ARISTADA INITIO for schizophrenia, LYBALVI for schizophrenia and bipolar I disorder, VIVITROL for alcohol and opioid dependence, and LUMRYZ for narcolepsy. The company also develops clinical and preclinical candidates for neurological disorders, including alixorexton for narcolepsy and idiopathic hypersomnia. Alkermes earns royalties and other revenue from products commercialized by partners, including Janssen’s long-acting INVEGA and RISPERDAL CONSTA products, which use its technologies, and Biogen’s VUMERITY for multiple sclerosis. Its technology platforms include injectable extended-release microspheres, LINKERX, NANOCRYSTAL, oral controlled release and MICROPUMP. Alkermes manufactures several products and RISPERDAL CONSTA microspheres at its Wilmington, Ohio facility, while using contract manufacturers for some products. In February 2026, it completed its acquisition of Avadel Pharmaceuticals, adding LUMRYZ and a narcolepsy commercial organization.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- DUBLIN 4, L2
- Fiscal year end
- December
- CIK
- 1520262
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Alkermes plc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Alkermes plc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Alkermes plc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Alkermes plc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Alkermes plc.'s last four quarterly filings that the numbers alone won't show?”